The chairman of pharmaceutical company Ipsen has said he is pleased with how the group has performed during 2007, and believes the firm will enjoy further growth in 2008.
Jean-Luc Belingard was speaking after it was announced that the company had entered the SBF 120 index, which regroups the 120 largest companies by market capitalisation and by trading volumes on Euronext Paris.
Mr Belingard said: “In 2007, we have continued to achieve all of our key objectives for the group’s development.
“Our partnership with Tercica in the US, strengthening our endocrine franchise, has well progressed.
“Following its approval by the FDA (Food and Drug Administration) in August, Somatuline Depot is now being launched throughout North America, whilst we have launched Increlex, now the reference treatment for severe primary IGF-1
deficiency, in the UK and Germany.
“We expect to have another very busy year in 2008, with potential recommendations from the CHMP (Committee for Human Medicinal Products) on febuxostat and on our botulinum toxin in Europe, and answers from the FDA on Reloxin and Dysport in the US.
“Furthermore, Ipsen will continue to demonstrate its long-term commitment to innovation with a yearly spend in research and development of 19 to 21% of its net sales going forward.”
Copyright © PA Business 2008